WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018050066) ABCG2 MONOCLONAL ANTIBODY AND USES THEREOF
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/050066    International Application No.:    PCT/CN2017/101549
Publication Date: 22.03.2018 International Filing Date: 13.09.2017
IPC:
C07K 16/18 (2006.01), C12N 5/20 (2006.01), C07K 14/47 (2006.01), A61K 39/395 (2006.01), A61P 35/00 (2006.01)
Applicants: PEKING UNIVERSITY [CN/CN]; No. 5 Yiheyuan Road, Haidian District Beijing 100871 (CN)
Inventors: ZHEN, Hongying; (CN)
Agent: BEIJING WANXIANGXINYUE INTELLECTUAL PROPERTY OFFICE; Room 1625, 6th Floor Beijing Resource Yanyuan Hotel No. 1 Yiheyuan Road, Haidian District Beijing 100080 (CN)
Priority Data:
201610827464.9 14.09.2016 CN
Title (EN) ABCG2 MONOCLONAL ANTIBODY AND USES THEREOF
(FR) ANTICORPS MONOCLONAL ABCG2 ET SES UTILISATIONS
(ZH) 一种ABCG2单克隆抗体及其用途
Abstract: front page image
(EN)Disclosed are an ABCG2 monoclonal antibody having the effects for resisting against tumors and for reversing drug resistance of the tumors, and uses thereof in novel tumor resisting drugs. Also disclosed is a new antigen sequence, used for inducing generation of a monoclonal antibody or a polyclonal antibody for the ABCG2. In addition, disclosed is a hybridoma for generating the ABCG2 monoclonal antibody having the effects for resisting against tumors and for reversing drug resistance of the tumors.
(FR)L'invention concerne un anticorps monoclonal ABCG2 ayant les effets de résistance aux tumeurs et d'inversion de la résistance aux médicaments des tumeurs, et ses utilisations dans de nouveaux médicaments résistant aux tumeurs. L'invention concerne également une nouvelle séquence d'antigène, utilisée pour induire la génération d'un anticorps monoclonal ou d'un anticorps polyclonal pour le ABCG2. De plus, l'invention concerne un hybridome pour générer l'anticorps monoclonal ABCG2 ayant les effets de résistance aux tumeurs et d'inversion de la résistance aux médicaments des tumeurs.
(ZH)公开了兼具抗肿瘤及逆转肿瘤抗药性作用的ABCG2单克隆抗体及其在作为新型抗肿瘤药物中的用途。还公开了一种新的抗原序列,其用于诱导产生针对ABCG2的单克隆或者多克隆抗体的产生。另外,公开了产生兼具抗肿瘤及逆转肿瘤抗药性作用的ABCG2单克隆抗体的杂交瘤。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)